drugset / Trial / NCT01814904

Dose-finding Study of MCI-196

NCT01814904

Phase 3 Terminated 10 enrolled Tanabe Pharma Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

The Primary Objective of this study is to determine the initial starting doses of colestilan (MCI-196) in paediatric subjects with Chronic Kidney Disease Stage 5 on Dialysis and with Hyperphosphataemia.

Timeline

Start
2014-04
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject COLESTILAN CHLORIDE Other / unclassified 3 g
Subject COLESTILAN CHLORIDE Other / unclassified 6 g
Subject COLESTILAN CHLORIDE Other / unclassified 9 g